Apotex Worldwide

About Us

For Media Inquiries, Please Contact:

Jordan Berman
Global Director,
Corporate Communications

Apotex Inc.
  4100 Weston Road,
North York,
ON, M9L 1P9
Canada
  416-401-7487
  Email

Press Center

Jun 12, 2017

Apobiologix Applauds Supreme Court Decision in Sandoz Biosimilar Case

Apobiologix, a division of the Apotex Group focused on biologics innovation, today announced their support of the Supreme Court decision in the Sandoz v Amgen case. The case clarifies the timing of the Biologics Price Competition and Innovation Act (BPCIA) requiring biosimilar companies to provide 180-days notice to the companies of the reference products of intent to market the biosimilar.
Jun 8, 2017

Canadian Scientists Honored for Role in Breakthrough Drug

Two Toronto scientists who spearheaded the research that brought a life-saving drug to patients around the world are being honored at the annual Cooley's Anemia Foundation Gala tonight in New York City.
Apr 28, 2017

University of Saskatchewan, Apotex renew partnership with $1.6M donation to the College of Pharmacy and Nutrition

The University of Saskatchewan and Apotex Inc. have renewed their partnership with a $1.6 million donation by the company to the College of Pharmacy and Nutrition.
Mar 8, 2017

Apotex Announces $184 Million Investment to Grow U.S. Manufacturing Presence; Expansion Plan Comprises Company's Largest Investment in the United States

Today Apotex Inc., the largest Canadian owned pharmaceutical company, announced the details of a $184 million U.S. expansion plan
Mar 31, 2016

Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets

Apobiologix^®, a Division of Apotex Inc., today launched Grastofil^®, its first subsequent entry biologic (SEB) approved in Canada.
Mar 24, 2016

Apotex Launches First Generic Version of Merck's Nasonex®

Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex^® nasal spray (mometasone furoate monohydrate) in the United States.